Episode

2025 Year in Review - Part 2

Podcast
Eyewire News: The Podcast
Published
Dec 31, 2025
Duration seconds
525
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/BMCL3297955984.mp3
Audio
https://traffic.megaphone.fm/BMCL3297955984.mp3
JSON
/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/2025-year-in-review-part-2
Markdown
/podcast/eyewire-news-the-podcast-7055536/2025-year-in-review-part-2.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/2025-year-in-review-part-2/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/2025-year-in-review-part-2.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Highlights from the last 6 months of 2025 include advancements of emerging technologies in glaucoma, the first pharmacologic treatment for myopia in Europe, the expansion of labels for anti-VEGF treatments, and the release of the DEWS III report exploring the diagnosis and management of dry eye disease. Learn more about your ad choices. Visit megaphone.fm/adchoices